This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These conclusions were presented as part of an abstract from the open-label, phase 3 CheckMate 816 trial (NCT02998528) at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, and subsequently published in the Journal of Clinical Oncology. J Clin Oncol. 2025;43(17). doi:10.1200/JCO.2025.43.17_suppl.LBA800.
Patients often present with peripheral blood, bone marrow, and splenic involvement. 5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. There is currently no universal standard of care for MCL.
1 The findings were presented at the Revolutionizing Atopic Dermatitis (RAD) 2025 conference held in Nashville, Tennessee. The results confirm nemolizumab’s use in increasing improvements in symptoms, such as itch and skin lesions, with prolonged treatment up to 2 years.
Alixorexton presents as a hopeful, potentially paradigm-shifting treatment for this population. In a sign of alixorexton’s tolerability, over 95% of patients who participated in this portion of the trial elected to join the ongoing 7-week, open-label extension.
Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling. Presented at: Hematology/Oncology Pharmacy Association 2025 Annual Conference; April 9-12, 2025; Portland, OR. REFERENCE Soefje SA.
The Opportunities, Gaps in Diabetes Care Making Pharmacists Stand Out | ADA 2025 Brian Nowosielski ; Jon Easter, RPh July 4th 2025 Podcast Following his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter caught up with Drug Topics to discuss the pharmacists’ role in diabetes management.
This change mirrored a January 2025 FDA safety alert and label update that urged providers to consider genetic testing, inform patients of the risks, and discuss available options. Demonstrating improved outcomes and cost-effectiveness helps ensure payer support and broadens access to precision therapies.
Limitations included open-label design and dosage constraints, but the multicountry approach enhanced generalizability and external validity. 1 “The limitations of this study were it being open-label, allowing potential assessment biases and the absence of blinded assessment of clinical endpoints. Additionally, SOCs with at least 2.5%
Because these conditions are linked—sustained hypertension may contribute to impaired kidney function, and progressive decrease in kidney function may lead to worsening blood pressure control—the risk of cardiovascular disease and mortality rises significantly when CKD is present in patients with hypertension.
The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." Clinical trials demonstrated tirzepatide's superior efficacy in A1C reduction and weight loss compared to placebo, semaglutide, and insulin glargine.
The findings from a phase 2 study (NCT04988815) were presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago. 2-5 In the multicenter, phase 2, open-label prospective study, researchers investigated ropeg-IFN-α2b treatment in patients with profibrotic MF or DIPSS low-intermediate-1 risk MF. FiercePharma.
It has 1 region that binds to CD3, a protein on T cells, a type of immune cell, and 2 regions that bind to CD20, a protein on B cells, which can either be healthy or malignant. Events that were considered consistent with immune effector cell-associated neurotoxicity syndrome occurred in 4 patients, all of which were concurrent with CRS.
2 However, Dalton noted that some procedures can change once a treatment is FDA-approved, with complications from Risk Evaluation and Mitigation Strategy programs as well as the occasional surprise on an FDA label. Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. Updated March 20, 2023.
These findings, which were presented at the 2025 American Society of Clinical Oncology in Chicago, Illinois, suggest that omitting carboplatin from treatment regimens could be an efficacious de-escalated neoadjuvant strategy in this patient population. If caught early, the cancer can often be treated and cured, according to Cleveland Clinic.
The data from an ongoing phase 1 LIMBER trial (NCT04279847) were presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago. Thus, researchers are investigating the clinical benefit of INCB057643 in combination with Janus kinase (JAK) inhibitors, a cornerstone of MF treatment.
In general, choosing a product that has broad spectrum on the label, covering both UV-A and UV-B rays and containing 20% zinc oxide, for her children will be optimal, especially for more sensitive areas of the skin. 4,5 CASE 4 Treating Insect Bites AK is an 18-year-old man presenting with pruritic lesions on his arms and legs.
1 Data from the study were presented at the American Diabetes Association’s 85th Scientific Sessions, which were held June 20-23 in Chicago, Illinois. 1 Data from the study were presented at the American Diabetes Association’s 85th Scientific Sessions, which were held June 20-23 in Chicago, Illinois. News Release. Corcept Therapeutics.
1] This inability to detox properly can trigger or worsen autoimmune symptoms, as these chemical exposures can trigger immune dysregulation. [2] to fluoride in my tap water, to hidden mold in my home, to my shampoo and deodorant (have you ever read those labels?!), From indoor pollutants like formaldehyde (yes, really!),
Higher levels of bad bacteria and lower levels of beneficial bacteria can contribute to the development of leaky gut , which we know is one of three things that must be present in order for autoimmune disease to develop (in addition to a genetic predisposition and an environmental trigger). [4]
The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois. The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois. months versus 2.1
Despite a high prevalence of childhood and youth-aged obesity, the use of medications for treating obesity is persistently low among children and young adults (YA), according to an abstract presented at the American Diabetes Association’s 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025. of adolescents and 5.7%
In the randomized, open-label, multicenter phase 3 NATALEE clinical trial (NCT05306340), ribociclib (Kisqali; Novartis) plus endocrine therapy, a nonsteroidal aromatase inhibitor (NSAI), significantly improved invasive disease-free survival among individuals with HR-positive (HR+) and HER2-negative (HER2-) early breast cancer.
By acting on hair follicle stem cells—which remain present even in balding areas—PP405 offers a promising option for people often left out by existing therapies. After the randomized portion of the study, patients were eligible to enroll in an open-label extension study for 3 months to assess the long term safety of PP405.
" 1 ALKAZAR is a global, randomized, controlled, open-label phase 3 trial studying neladalkib in TKI-naïve patients with advanced ALK-positive NSCLC. Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines. J Clin Oncol.
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June 12 to 15 June in Milan, Italy, preliminary dose-escalation and optimisation results from the global, multicentre, open-label, single-arm Phase I/II SYRUS clinical trial (NCT06137118) were presented on the second day.
Biologic drugs used to treat plaque psoriasis are used off-label in GPP, but there’s little data on their effectiveness. In some cases the consequences are fatal, and at the moment there are no approved therapies in the US or Europe for GPP flares.
Despite improvements in screening, surveillance rules, and imaging, more than two-thirds of patients with HCC present with advanced disease at diagnosis, BeiGene said. The RATIONALE 301 Phase III randomised, open-label study included more than 600 patients in the US, Europe and Asia. About tislelizumab.
This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks.
This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks.
The integration of real-time track and trace technology, handheld mobile smart devices and advanced analytics solutions into the COVID-19 vaccine rollout is our best shot to enhance the global vaccination effort and combat new variants with herd immunity. Critical supply chain visibility.
RP2 oncolytic mono-therapy provides an objective response in a small number of patients as well as in combination with nivolumab according to findings presented at the recent European Society for Medical Oncology congress. Consequently, blockage of CTLA-4 function promotes immune-mediated tumour regression.
Findings presented at EADVC 2022. Almirall has previously found state-of-the-art therapies for immune-related inflammatory diseases such as hidradenitis suppurativa, alopecia areata, psoriasis, and vitiligo.
Reflecting on recent clinical milestones, Dalsgaard noted that in February Vicore presented efficacy data from its ongoing Phase II2a AIR clinical trial of C21 in IPF. In May, Vicore reported new 36-week data from the AIR multi-centre clinical trial in a presentation at the American Thoracic Society (ATS) international congress.
The approval was based on the findings from the randomised, multicentre, open-label, international Phase III POSEIDON trial. A human monoclonal antibody (mAb), Imfinzi attaches to the PD-L1 protein and hinders its interaction with the PD-1 and CD80 proteins, preventing the immune-evading strategy of the tumour.
While the data will be presented at an upcoming meeting, a previous analysis of the two arms for OS showed an HR of 0.59, which could lead to a modest but clinically meaningful improvement in OS. Adverse events (AEs) were balanced between the arms, except for immune-related AEs, which were more frequent in the Tuoyi arm (grade ≥ 3, 8.9%
It’s part of the immune system’s defense mechanism, but it can cause serious issues—like rheumatoid arthritis and psoriatic arthritis—if it gets too severe. Rinvoq is a Janus kinase (JAK) inhibitor, which means it blocks certain enzymes that cause the immune system to create inflammation. Inflammation is a double-edged sword.
Viral infections: Oftentimes, chills precede a fever and can be a sign that your immune system is trying to fight something off. Bacterial infections: Chills may also be present during a bacterial infection, such as a urinary tract infection (UTI), strep throat, pneumonia (which can be caused by a virus or bacteria), and even sepsis. (If
Biologics are designed to target specific immune system proteins that can cause certain reactions. The immune system releases those proteins in response to potential allergens entering the body. This causes the immune system to overreact, leading to skin irritation.
Enzymes are a form of protein present throughout the body. Her body was making numerous inflammatory immune complexes to EVERY protein she was eating! When someone is not properly digesting fats, they will often present with diarrhea, steatorrhea (fat in stools), cramping, bloating, and muscle cramps. The Role of Enzymes.
Suppressing your own immune system by taking medication is naturally frightening but is absolutely necessary to control many autoimmune conditions. By blocking TNF, the drug disrupts the chemical messaging between the body’s immune cells which blunts the inflammation our immune system can produce. Plaquenil coupons.
Vitamin D supports the immune system by enhancing the pathogen-fighting effects of white blood cells, which are important parts of immune defense. When it leaks into the bloodstream, the body does not recognize it, and labels the structure as a foreign invader and attacks it. It’s also great for boosting our immunity!
8) In very simple terms, this theory hypothesizes that our immune system begins to attack our own thyroid gland because we are infected with a pathogenic organism (like a bacterium, parasite , or virus ), that looks similar to components of the thyroid gland. 10) All three are required to be present for an autoimmune condition to manifest.
I knew he was right — sugar can contribute to a yeast overgrowth, lowered immunity, blood sugar issues, weight gain, diabetes, and a whole host of health problems (1-3) — but I was a sugar addict, and it was devastating to think that I would have to let go of this old friend and not have any sweetness in my life. What About Other Sweeteners?
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content